Effects of the gastrin-releasing peptide antagonist RC-3095 in a rat model of ulcerative colitis

Digestive Diseases and Sciences

Volumn 55, Issue 8, 2010, Pages 2203-2210

  Damin, Daniel C ^a   Santos, Frederico S ^a   Heck, Renata ^a   Rosito, Mário A ^a   Meurer, Luise ^b   Kliemann, Lúcia M ^b   Roesler, Rafael ^b   Schwartsmann, Gilberto ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Bombesin like peptides; Gastrin releasing peptide; Inflammatory bowel disease; RC 3095; Ulcerative colitis

Indexed keywords

ACETIC ACID; DEXAMETHASONE; INTERLEUKIN 1BETA; MESALAZINE; RC 3095; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; ULCERATIVE COLITIS;

ANIMALS; BOMBESIN; COLITIS, ULCERATIVE; COLON; FEMALE; GASTRIN-RELEASING PEPTIDE; IMMUNOHISTOCHEMISTRY; MALE; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR;

EID: 77954424878     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1032-9     Document Type: Article

References (36)

1. DK Podolsky 2002 Inflammatory bowel disease N Eng J Med 347 417 429 10.1056/NEJMra020831 1:CAS:528:DC%2BD38XlvFKrt7s%3D (Pubitemid 34851835)
2. C Fiocchi 1998 Inflammatory bowel disease: etiology and pathogenesis Gastroenterology 115 182 205 10.1016/S0016-5085(98)70381-6 1:STN:280: DyaK1czitlGjtg%3D%3D 9649475 (Pubitemid 28307304)
3. E Louis 2001 The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterization, genetics and clinical application: focus on TNF-alpha Acta Gastroenterol Belg 64 1 5 1:STN:280:DC%2BD3M3jtVCitw%3D%3D 11322060 (Pubitemid 32291096)
4. HC Reinecker M Steffen T Witthoeft 1993 Enhanced secretion of TNF-alpha, IL-6, and IL-1 by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease Clin Exp Immunol 94 174 181 1:CAS:528:DyaK3sXms1yltbw%3D 8403503 (Pubitemid 23308385)
5. BE Sands GG Kaplan 2007 The role of TNF-α in ulcerative colitis J Clin Pharmacol 47 930 10.1177/0091270007301623 1:CAS:528:DC%2BD2sXps1Sjtb8%3D 17567930 (Pubitemid 47094091)
6. D Seegers G Bouna AS Pena D Seegers G Bouna AS Pena 2002 A critical approach to new forms of treatments of Crohn's disease and ulcerative colitis Aliment Pharmacol 16 53 58 10.1046/j.1365-2036.16.s4.8.x (Pubitemid 34595619)
7. S Katz 2007 "Mind the Gap": an unmet need for new therapy in IBD J Clin Gastroenterol 41 799 809 10.1097/MCG.0b013e318033d71d 17881924 (Pubitemid 47442704)
8. DB Cornelio R Roesler G Schwartsmann 2007 Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann Oncol 18 1457 1466 10.1093/annonc/mdm058 1:STN:280:DC%2BD2srgvFenuw%3D%3D 17351255 (Pubitemid 47365477)
9. WP Ter Beek ES Muller RA van Hogezand et al. 2004 Gastrin releasing peptide receptor expression is decreased in patients with Crohn's disease but not in ulcerative colitis J Clin Pathol 57 1047 1051 10.1136/jcp.2003.014993 1:CAS:528:DC%2BD2cXps1Kls7s%3D 15452158 (Pubitemid 39331354)
10. M De la Fuente M Del Rio MD Ferrandez et al. 1991 Modulation of phagocytic function in murine peritoneal macrophages by bombesin, gastrin-releasing peptide and neuromedin C Immunology 73 205 211 1649124
11. EA van Tol HW Verspaget CB Lamers 1990 Neuropeptide regulation of cell-mediated cytotoxicity against human tumor cells Neuropeptides 16 25 32 10.1016/0143-4179(90)90026-U 1701225 (Pubitemid 20186604)
12. EA van Tol CV Elzo Kraemer HW Verspaget et al. 1991 Intravenous administration of bombesin in man stimulates natural killer cell activity against tumour cells Neuropeptides 18 15 21 10.1016/0143-4179(91)90158-F 2046885
13. F Dal Pizzol LP Di Leone C Ritter et al. 2006 Gastrin-releasing peptide receptor antagonist effects on an animal model of sepsis Am J Respir Crit Care Med 173 84 90 10.1164/rccm.200507-1118OC 1:CAS:528:DC%2BD28XmslSktrk%3D 16192447 (Pubitemid 43069792)
14. K Fujino Y Takami SG de la Fuente et al. 2004 Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis J Gastrointest Surg 8 842 847 10.1016/j.gassur.2004.07.011 15531237 (Pubitemid 41115737)
15. R González S Rodríguez C Romay 1999 Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats Parmacol Res 39 55 59 10.1006/phrs.1998.0409 (Pubitemid 29101335)
16. KC Bhol PJ Schechter 2007 Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis Dig Dis Sci 52 2732 2742 10.1007/s10620-006-9738-4 1:CAS:528:DC%2BD2sXhtVSisLrN 17436088 (Pubitemid 47373915)
17. R Fabia R Willén A Ar'Rajab et al. 1992 Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis Eur Sur Res 24 211 225 10.1159/000129209 1:CAS:528:DyaK3sXnvVCgsQ%3D%3D
18. AD Millar DS Rampton CL Chander et al. 1996 Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis Gut 39 407 415 10.1136/gut.39.3.407 1:CAS:528:DyaK28XntFekur0%3D 8949646
19. E Sekizuka MB Grisham M Li et al. 1988 Inflammation-induced intestinal hyperemia in the rat: role of neutrophils Gastroenterology 95 1528 1534 1:STN:280:DyaL1M%2FjtFyjug%3D%3D 2846403 (Pubitemid 19016211)
20. LA Dieleman CO Elson GS Tennyson et al. 1996 Kinetics of cytokine expression during healing of acute colitis in mice Am J Physiol 271 G130 G136 1:CAS:528:DyaK28Xkslynsr0%3D 8760116
21. BR MacPherson CJ Pfeifer 1978 Experimental production of diffuse colitis in rats Digestion 17 135 150 10.1159/000198104 1:CAS:528:DyaE1cXmtVyktA%3D%3D 627326
22. R Kojima S Hamamoto M Morikawi et al. 2001 The new experimental ulcerative colitis model in rats induced by sub-serosal injection of acetic acid Folia Parmacol J 118 123 130 10.1254/fpj.118.123 1:CAS:528:DC%2BD3MXlslyns78%3D (Pubitemid 32734657)
23. N Gonzalez TW Moody H Igarashi et al. 2008 Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states Curr Opin Endocrinol Diabetes Obes 15 58 64 1:CAS:528:DC%2BD1cXitFKgsrg%3D 18185064
24. M Del Rio M De la Fuente 1994 Chemoattractant capacity of bombesin, gastrinreleasing peptide and neuromedin C is mediated through PKC activation in murine peritoneal leukocytes Regul Pept 49 185 193 10.1016/0167-0115(94)90140-6 1:CAS:528:DyaK2cXhsFCgs7s%3D 8140272 (Pubitemid 24035009)
25. M Subramaniam C Bausch A Twomey et al. 2007 Bombesin-like peptides modulate alveolarization and angiogenesis in bronchopulmonary dysplasia Am J Respir Crit Care Med 76 902 912 10.1164/rccm.200611-1734OC (Pubitemid 350097080)
26. F Meloni R Bertoletti A Corsico et al. 1992 Bombesin/gastrin releasing peptide levels of peripheral mononuclear cells, monocytes and alveolar macrophages in chronic bronchitis Int J Tissue React 14 195 201 1:CAS:528:DyaK3sXkt1Gks7w%3D 1478797 (Pubitemid 23003850)
27. F Petronilho R Roesler G Schwartsmann et al. 2007 Gastrin-releasing peptide receptor as a molecular target for inflammatory diseases Inflamm Allergy Drug Targets 6 197 200 10.2174/187152807783334319 1:CAS:528: DC%2BD1cXntFagsr4%3D 18220954 (Pubitemid 46952449)
28. O Grimsholm S Rantapaa-Dahlqvist S Forsgren 2005 Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis Arthritis Res Ther 7 R416 R426 10.1186/ar1503 15899028
29. PG Oliveira CV Brenol MI Edelweiss et al. 2008 Effects of an antagonist of the bombesin/gastrin-releasing peptide receptor on complete Freund's adjuvant-induced arthritis in rats Peptides 29 1726 1731 10.1016/j.peptides. 2008.05.031 1:CAS:528:DC%2BD1cXhtFCkurrN 18590783
30. DK Podolsky 2002 The current future understanding of inflammatory bowel disease Best Pract Res Clin Gastroenterol 16 933 943 10.1053/bega.2002.0354 12473299 (Pubitemid 37554773)
31. WJ Sandborn SB Hanauer 1999 Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 5 119 133 1:STN:280:DyaK1M3mvVOjsQ%3D%3D 10338381
32. TT MacDonald P Hutchings MY Choy et al. 1990 Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine Clin Exp Immunol 81 301 305 1:CAS:528: DyaK3cXlsFSmtrg%3D 2117510 (Pubitemid 20242538)
33. EJ Breese CA Michie SW Nicholls et al. 1994 Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease Gastroenterology 106 1455 1466 1:STN:280:DyaK2c3lt1Cquw%3D%3D 8194690
34. SH Murch CP Braegger JA Walker-Smith et al. 1993 Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease Gut 34 1705 1709 10.1136/gut.34.12.1705 1:STN:280:DyaK2c7gvFOmug%3D%3D 8031350
35. PT Schmidt T Ljung B Hartmann et al. 2005 Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY Eur J Gastroenterol Hepatol 17 207 212 10.1097/00042737-200502000-00012 1:CAS:528: DC%2BD2MXntVSrug%3D%3D 15674099 (Pubitemid 40349535)
36. G Schwartsmann LP DiLeone M Horowitz et al. 2006 A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies Invest New Drugs 24 403 412 10.1007/s10637-006-6886- 5 1:CAS:528:DC%2BD28XlsVCisb8%3D 16505950 (Pubitemid 43876076)